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Abstract        
 
Atherosclerosis is accelerated in the setting of diabetes but the factors driving this 
phenomenon remain elusive. Hyperglycemia leads to elevated levels of transforming 
growth factor-β (TGF-β) and TGF-β has been implicated as a factor in atherosclerosis. 
Given the established association between hyperglycemia and elevated TGF-β it is 
plausible that elevated TGF-β levels in diabetes play a pathogenic role in the 
development of accelerated atherosclerosis in diabetes. TGF-β is a potent regulator of 
extracellular matrix synthesis, including many actions on proteoglycan synthesis 
which lead to increased binding to LDL and therefore potentially increased lipid 
retention in the vessel wall and accelerated atherosclerosis. TGF-β signals through the 
canonical TGF-β receptor I (TβRI/Alk V) mediated phosphorylation of Smad 
transcription factors and is also known to involve, positively and negatively, 
interactions with the Mitogen Activated Protein (MAP) kinase pathways. This review 
will focus on the effects of TGF-β on proteoglycan synthesis in vascular smooth 
muscle and particularly the signaling pathways through which TGF-β exerts its effects 
because those pathways may be therapeutic targets for the prevention of pathological 
modifications in the proteoglycan component of the vessel wall in the vascular 
diseases of diabetes. 
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Introduction 
Cardiovascular disease is the largest single cause of premature mortality in 
developed nations 1. World-wide increases in obesity, metabolic syndrome and 
diabetes are driving higher rates of cardiovascular disease 2,3. Individuals with 
diabetes have numerous acute issues such as hypoglycemic events however the main 
impact of diabetes on health is through the development of its microvascular 
(retinopathy, nephropathy, neuropathy and impotency) and macrovascular 
(myocardial infarction, stroke) complications 4,5. The major manifestation of 
cardiovascular disease or coronary artery disease is an acute myocardial infarction 
leading to death or subsequently heart failure. Atherosclerosis, the underlying 
pathology of macrovascular disease, is accelerated by the plasma milieu and other 
factors associated with diabetes resulting in higher levels of cardiovascular disease in 
this group 6,7.  Acute ischemic events have a more profound effect in people with 
diabetes because of the more pervasive vascular disease and the higher susceptibility 
of the myocardium to the effects of ischemia 8,9. The underlying pathology is 
atherosclerosis, the slow accumulation of cholesterol in the sub-endothelium of the 
artery wall and the development over several decades of complex lesions termed 
plaques 7,10-14. Some plaques are labile and the rupture of such so-called vulnerable 
plaques leads to the adverse clinical event 15,16. The extended risk factors include 
cigarette smoking, hypertension, hyperlipidemia and hyperglycemia and non-
modifiable factors such as age and genetic predisposition 17. Medical therapies are 
based on lowering risk factors and anti-hypertensives and anti-hyperlipidemia agents 
are quite efficacious 18,19. The role of glucose and hyperglycemia in driving 
accelerated atherosclerosis and increased rates of CVD are well established both 
epidemiologically 20 and investigationally such as the recent study of Intravascular 
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Ultrasound (IVUS) of plaque progression in people with diabetes 21.  However, in 
contrast to the established efficacy of agents which lower plasma cholesterol and 
blood pressure the role of anti-hyperglycemic agents in preventing cardiovascular 
disease is highly controversial 22,23. The reasons for this are most perplexing 24.  Thus, 
in spite of multiple therapies, rates of cardiovascular events are still high and a better 
understanding of the drivers of atherosclerosis in the setting of diabetes is required 
and this will hopefully lead to the identification of new targets and ultimately new 
treatment modalities. 
There are several theories in relation to the origins of atherosclerosis. These 
include the Response to Injury hypothesis of Ross and Glomset 25, Response to 
Retention Hypothesis of Tabas, Williams and later Boren 13,26, the oxidation 
hypothesis 27and the role of hyperglycemia and Advanced Glycation End (AGE) 
products 28,29. The major processes initiating atherosclerosis are the initial deposition 
and accumulation of lipid in the vessel wall 30 and the subsequent inflammatory 
response which ultimately generates the complex and sometimes labile plaques 
11,12,15,16. Nakashima et al. 31 demonstrated that in human coronary arteries the 
deposition of lipid occurs before the inflammatory response and the deposited 
apolipoproteins associated with the lipid co-localize with proteoglycans specifically 
biglycan and decorin 31. Thus the extracellular matrix and in particular the lipid-
binding proteoglycan component is altered in the neointima of atherosclerosis 
susceptible arteries and it forms the permissive environment for the initiation of 
atherosclerosis 14,32,33. Whether or not the initial lipid retention by proteoglycans is the 
forerunner of the inflammatory response or the inflammatory response is independent 
is unknown. The former alternative seems more likely and if so then proteoglycan to 
Page 5 of 24 
lipid interaction is integral to the initiation of atherosclerosis and potentially 
represents a therapeutic target for the prevention of the disease process 34,35.  
The impact of the factors associated with diabetes on the production of 
proteoglycans by VSMCs has been investigated in detail by Tannock, Little and 
colleagues 36-39. Surprisingly, many of the obvious factors, including hyperglycemia, 
have no effect on proteoglycan synthesis and structure under the conditions so far 
investigated 36,37. Glucosamine, investigated as a component of the hexosamine 
pathway, has the potential to act as a precursor for glycosaminoglycan (GAG) 
synthesis and thus increase proteoglycan and GAG chain synthesis 40. Our studies 
actually found that it has the opposite effect and exogenous glucosamine causes 
concentration dependent inhibition of GAG elongation 36 which we later showed to be 
due to competition with glucose uptake leading to cellular ATP depletion 38. Elevated 
free fatty acids are a component of the early dysmetabolic status of diabetes 41 and 
free fatty acids also have a modest effect on proteoglycan synthesis in VSMC 42.  
The major effect of the diabetic milieu appears to be indirect due to the action of 
high glucose concentrations to stimulate the secretion of TGF-β 37,43. The 
hyperglycemia in patients with Type 2 diabetes leads to increased renal production of 
TGF-β 43. TGF-β is a potent regulator of extracellular matrix synthesis, including 
many actions on proteoglycan synthesis 39,44-47.  TGF-β induces changes in the 
proteoglycans secreted by VSMCs leading to increased binding to LDL 39 and 
therefore potentially increased lipid retention in the vessel wall and accelerated 
atherosclerosis 14. TGF-β has been implicated in many diseases including tumor 
metastasis and renal and cardiac fibrosis 48-50. Hyperglycemia has also been linked to 
activation of TGF-β signaling pathways regulating processes associated with the 
complications of diabetes 51. TGF-β is strongly implicated in atherosclerosis and it is 
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highly expressed in atherosclerotic plaques (see Fig. 1). TGF-β and its receptors are 
present in atherosclerotic lesions 52 and play an important role in regulating vessel 
proteoglycan synthesis and lipoprotein retention 52,53. Thus, given the established 
association between hyperglycemia and elevated TGF-β 43, it is plausible that elevated 
TGF-β levels in diabetes plays a pathogenic role in the development of accelerated 
atherosclerosis in diabetes. On this basis we have reviewed the actions of TGF-β on 
proteoglycan synthesis in VSMC as a surrogate for the effects of the diabetic milieu 
on the vascular extracellular matrix. This review will focus on the effects of TGF-β on 
proteoglycan synthesis in vascular smooth muscle and particularly the signaling 
pathways through which TGF-β exerts its effects because those pathways may be 
therapeutic targets for the prevention of pathological modifications in the 
proteoglycan component of the vessel wall in diabetic vascular disease. 
 
TGF-β and TGF-β receptors 
TGF-β is a multifunctional growth factor that controls cellular processes 
involved in proliferation, differentiation, apoptosis, extracellular matrix accumulation 
and the immune system  49,50,54. The TGF-β superfamily of ligands include: Bone 
morphogenetic proteins (BMPs), Growth and differentiation factors (GDFs), Anti-
müllerian hormone (AMH), Activin, Nodal and TGF-βs 55.  TGF-β is a secreted 
protein that exists in three isoforms called TGF-β1, TGF-β2 and TGF-β3. Three 
isoforms are highly conserved in mammals, and deletion of the isoforms in mice leads 
to distinct phenotypes 56-58. All three TGF-βs are synthesized as precursor molecules 
containing an N-terminal propeptide region in addition to the TGF-β homodimer 59. 
The N-terminal signal peptide (propeptide region) consists of a 20-30 amino acid 
domain called latency associated peptide (LAP) required for secretion from the cell 
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and a 112-114 amino acid C-terminal region that becomes the mature TGF-β 
molecule following its release from the propeptide region by proteolytic cleavage 60. 
TGF-β homodimer interacts with a LAP forming a complex called Small Latent 
Complex (SLC). This complex remains in the cell until it is bound by a protein called 
Latent TGF-β-Binding Protein (LTBP), forming a larger complex called Large Latent 
Complex (LLC). It is LLC that get secreted to the extracellular matrix 61. In most 
cases, before the LLC is secreted, the TGF-β precursor is cleaved from the propeptide 
but remains attached to it by noncovalent bonds 62. After its secretion, it remains in 
the extracellular matrix as an inactivated complex containing both the LTBP and the 
LAP which need to be further processed in order to release active TGF-β 63. 
TGF-β receptors are the major family of cell surface receptors which are 
serine/threonine kinases but they also possess weak tyrosine kinase activity 64. They 
exist in several different isoforms that can be homo- or heterodimeric 65. Receptor 
types I (TβRI) and II (TβRII) are signaling receptors consisting of an N-terminal 
extracellular ligand binding domain, a transmembrane region and a C-terminal 
serine/threonine kinase domain. TβRI , but not TβRII receptors contain a GS domain 
(cytosolic and immediately N-terminal to the kinase domain) which consists of a 
series of about thirty glycine-serine repeats 54. TGF-β receptor type III is the most 
abundant and a non-signaling receptor which plays a role in transferring TGF-β to its 
signaling receptors and has a high affinity for both TGF-β1 and TGF-β2 66. Type III 
receptors are membrane proteoglycans that carry heparan and chondroitin sulfate 
GAG chains. The binding site for TGF-β resides in the 100-120-kDa core polypeptide 
of this receptor. The type III receptor is highly sensitive to cleavage by trypsin. 
Trypsin action releases the GAG-containing domain of the receptor leaving a 60-kDa 
membrane-associated domain that contains the cross-linked ligand 66. 
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In mammals there are seven known type I receptors and five type II receptors 67. 
Signaling begins with a TGF-β ligand binding to a constituitively active type II 
receptor dimer, which recruits a type I receptor dimer forming a hetero-tetrameric 
complex with the ligand on the cell surface. The binding of a TGF-β family ligand 
causes the rotation of the receptors so that their cytoplasmic kinase domains are 
arranged in a catalytically favorable orientation. This enables the type II receptor to 
phosphorylate multiple serine and threonine residues in the GS region of the type I 
receptor.  
TGF-β signals via the TβRI/Alk V receptor and the canonical Smad pathway 
involving extreme C-terminal phosphorylation of receptor-regulated (R)-Smad 
transcription factors and translocation of Smad complexes to the nucleus where they 
regulate transcription 50,54. TβRI can also activate Mitogen Activated Protein (MAP) 
kinases leading to the phosphorylation of R-Smads in their linker region, a response 
that can inhibit or promote TGF-β signaling 68. The latter pathway is known 
somewhat incongruously as non-Smad or Smad independent signaling 
notwithstanding that it involves ultimately Smad phosphorylation. 
 
The Smad family and TGF-β signaling via phosphorylation of Smad carboxyl 
terminal 
The activated type I receptor phosphorylates cytoplasmic proteins of the C-
terminal regions of Smad family. Smads are a class of proteins that modulate the 
activity of TGF-β ligands and consist of three domains: (1) an N-terminal Mad-
homology 1 (MH1) domain which carries nuclear localization signals (NLS) and a 
DNA-binding domain; (2) a linker region of variable sequence and length that interact 
with prolyl-isomerases and ubiquitin ligases;  (3) a C-terminal MH2 domain which 
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binds to type I receptor and mediates Smad homo- and hetero-oligomerization as well 
as mediates the transactivation of nuclear Smad complexes 69. There are three classes 
of Smad: (1) the receptor-regulated Smads (R-Smad) which include Smad1, Smad2, 
Smad3, Smad5 and Smad9 (sometimes referred to as Smad8) 70; (2) the common-
mediator Smad (co-Smad) which includes only Smad4, which interacts with R-Smads 
to participate in signaling 71;  (3) The antagonistic or inhibitory Smads (I-Smad) which 
include Smad6 and Smad7, which block the activation of R-Smads and Co-Smads and 
can also signal-terminating initiate degradation 72. There are five receptor regulated 
Smads. TGF-βs, Activins, Nodals and some GDFs are mediated by Smad2 and Smad3, 
while BMPs, AMH and a few GDFs are mediated by Smad1, Smad5 and Smad9.  
The C-terminal phosphorylation of receptor activated R-Smads allows them to 
bind the   co-Smad, Smad 4. This resulting R-Smad/co-Smad complex which consist 
of trimers of two R-Smads and one Smad4, is then imported into the nucleus where 
they act as transcription factors and participate in the regulation of target gene 
expression 50. 
 
TGF-β signaling via phosphorylation of the Smad2 linker region  
TGF-β signaling is also known to involve positively and negatively in 
interaction with Mitogen Activated Protein (MAP)/ Extracellular signal-Regulated 
Kinases (ERK) pathway 50,54,73. TGF-β stimulates the phosphorylation of ERK1/2 73; 
the activated ERK then phosphorylates Smad2 on threonine residues and possibly 
serine residues in the linker region which can induce the expression of the inhibitory 
I-Smads, Smad 6 and Smad7, that can hinder the translocation of the Smad2 into the 
nucleus and resistance to TGF-β signaling 73.  
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Proteoglycans  
Proteoglycans are glycosylated proteins which have covalently attached highly 
anionic GAGs 74. Many forms of proteoglycans are present in all extracellular 
matrices of connective tissues including the blood vessel wall, where they are a 
component of the extracellular matrix as well as a cell-surface component of vascular 
cells. The major biological function of proteoglycans derives from the 
physicochemical characteristics of the core protein and carbohydrate components of 
the molecule. Core proteins determine the cellular location and serve as scaffolds for 
the GAG chains and the highly ionic chains determine physical properties of tissues 
and bind factors including growth factors and apolipoproteins.  The GAG chains are 
long, linear carbohydrate polymers that are highly negatively charged under 
physiological conditions, due to the occurrence of sulfate and uronic acid groups. The 
complementary roles of core protein and GAG are exemplified by the observation that 
binding of low-density lipoprotein (LDL) to GAG chains of intact proteoglycans 
occurs with an order of magnitude higher affinity than the binding to free GAG chains 
75.   
Proteoglycans can be categorized depending upon the nature of their GAG 
chains.  These chains may be: chondroitin sulfate, decorin sulfate, heparan sulfate and 
keratan sulfate. Proteoglycans have distinct biological functions and their involvement 
in many aspects of cell and tissue activities has been demonstrated. For example, 
aggrecan, forms a substantial structural component of cartilage and is composed of 
both decorin sulfate and keratan sulfate GAG chains. Large chondroitin sulfate 
proteoglycan, versican, is prominent in blood vessels 76. The smaller leucine-rich 
proteoglycans includes biglycan and decorin, which are widely distributed in many 
connective tissues, may have functions in regulating collagen fibril formation and in 
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modifying the activity of TGF-β 77. Perlecan, the major heparan sulfate proteoglycan 
in the glomerular basement membrane, may play an important role as the major 
anionic site responsible for the charge selectivity in glomerular filtration 78.  
Vascular smooth muscle cells isolated and passaged from human vessels, secrete 
predominantly the small chondroitin/decorin sulfate proteoglycans: biglycan, decorin, 
lesser amounts of versican and heparan sulfate proteoglycan, perlecan 79. TGF-β 75 
and oxidized LDL 80 regulate the GAG chains elongation and the proportion of the 
chondroitin/decorin sulfate proteoglycans in the component mixture of secreted 
proteoglycans. These effects lead to enhanced binding of proteoglycans to atherogenic 
apolipoproteins 81. In the initiation of atherosclerosis, the growth factor-modified 
biglycan with elongated GAG chains has been termed by us as “hyperelongated 
biglycan” 25. The modifications to GAGs on chondroitin sulfate and decorin sulfate 
proteoglycans increases the binding of GAGs to apolipoproteins 75,81,82; the hydrolytic 
and proteolytic modifications of apolipoproteins increase the binding strength of 
GAGs to LDL 80,83.   
 
Actions of TGF-β on proteoglycan synthesis in vascular smooth 
muscle 
Actions of TGF-β on proteoglycan synthesis 
TGF-β stimulates proteoglycan synthesis, specifically the expression of biglycan 
and an elongation of its decorin sulfate (DS) GAG chains and this results in an 
increased binding of the proteoglycan to LDL 39,44,46,47. In very early studies, Wight 
and colleagues 44,45 found that TGF-β causes a 3.3-fold increase in radiosulfate 
incorporation into biglycan in monkey arterial smooth muscle cells, but as expected it 
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had no effect on core protein size. Northern blotting analysis also revealed a more 
than two fold increase in biglycan mRNA expression 45. TGF-β had no appreciable 
effect on decorin core protein synthesis or GAG elongation on decorin 45. We have 
confirmed and extended these findings in human VSMCs 46,47. TGF-β increases 
radiosulfate incorporation into biglycan, associated with a marked increase in 
proteoglycan size which is specifically associated with an increase in the size of the 
GAG chains 39,47. TGF-β also increases [35S]-methionine/cysteine incorporation 
indicating an increase in core protein synthesis 46 and consistent with the induction of 
biglycan mRNA first described by Schonherr et al. 45. All responses to TGF-β are 
concentration-dependently inhibited by the TβRI/Alk V inhibitor SB431542 
indicating that they arise from TβRI/Alk V 46.  
 
TGF-β receptor signaling pathway regulating biglycan synthesis  
TGF-β can also activate MAP kinases leading to downstream signaling 
completely independent of Smads but also causing phosphorylation of Smads in the 
linker region 50 a response originally associated with the inhibition of Smad 
translocation to the nucleus and this is antagonistic to TGF-β signaling 73. We recently 
investigated the ability of TGF-β to stimulate the phosphorylation of p38, 
Extracellular signal-Regulated Kinases (ERK) and Jun N-terminal Kinase (JNK) 
MAP kinases as well as Smad2 phosphorylation at both its C-terminal and in the 
linker region 47. TGF-β stimulated the phosphorylation of all three MAP kinases 47. 
Pharmacological inhibition of ERK and p38 MAP kinase blocked TGF-β mediated 
GAG elongation and expression of biglycan whereas inhibition of JNK had no effect. 
Inhibition of ERK and p38 but not JNK MAP kinases attenuated the effect of TGF-β 
to increase phosphorylation of Smad2 linker region 47. High levels of phosphorylation 
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of Smad2 linker region were detected in a nuclear fraction of TGF-β treated cells 
implying that this response was not antagonistic to TGF-β signaling. Thus, TGF-β 
signaling via ERK and p38 MAP kinases and leading to the phosphorylation of the 
linker region of Smad2 mediates its effects of TGF-β on biglycan synthesis and GAG 
elongation in human vascular smooth muscle cells 47. We have also demonstrated that 
the size of the effect mediated by the signaling pathways is sufficient to alter binding 
to LDL because the binding of radiolabelled proteoglycans to normal human LDL is 
reduced in proteoglycan harvested from cells treated with inhibitors of the TGF-β 
receptor (TβRI) or p38 MAP kinase 46. 
 
Consequences of TGF-β stimulated proteoglycan synthesis: increased 
lipid binding  
TGF-β has two actions on proteoglycan synthesis which can enhance the 
atherogenicity of the extracellular matrix. TGF-β  stimulates the expression of 
biglycan which is the proteoglycan most closely associated  with lipid binding in early 
human atherosclerosis 30 and TGF-β also stimulates the elongation of GAG chains 
leading to hyperelongated chains which show enhances binding in to LDL 14,39,84.  
Highly anionic (sulfated and carboxylated) GAG chains on proteoglycans bind to a 
multitude of molecules but practically and of interest to the development of 
atherosclerosis they bind to cationic residues on the apolipoproteins (B100) on human 
LDL 85,86.  Lipids bind to the GAGs in the vessel wall 87. Due to the complex nature of 
the interacting species it is difficult to describe the interaction in classical 
receptor-binding terms but when an equal quantity of radiolabelled proteoglycan core 
proteins from control and TGF-β treated cells is added to an in vitro gel mobility shift 
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assay then the latter show higher affinity binding as evidenced by a shift to the left of 
the binding isotherm 39. The rate limiting step for  passages of lipoproteins through the 
vessel wall is the release from the wall to the lymph so an increase in binding affinity 
will delay the transition of the lipid and ultimately induce the inflammatory response 
that generates the complex plaques 88.  
As described above, TGF-β signaling involves Smad transcription factors acting 
through the canonical C terminal phosphorylation pathways but also as shown 
recently by us potentially via the TGF-β-stimulated MAP kinase (p38 and Erk) 
mediated phosphorylation of the linker region of Smad2 47. Multiple other hormones 
and growth factors activate MAP kinases in VSMCs and these have the potential to 
cause Smad linker phosphorylation. Such a response might synergize with the actions 
of TGF-β in diabetes and indeed we have reported that the actions of TGF-β and 
PDGF are additive in causing GAG elongation on biglycan 34 and by extrapolation 
causing increased binding to LDL. Thus, hyperglycemia driven increased level of 
TGF-β can synergize with other factors known to be elevated in diabetes to drive 
hyperelongation of GAG chains on lipid binding proteoglycans (see schema in Fig. 2) 
and thus has the potential to be the driving factor and the link between hyperglycemia 
and accelerated development of atherosclerosis in diabetes 89 
 
Conclusions 
Proteoglycans are complex molecules being comprised of both protein and 
carbohydrate moieties. These entities have completely different synthetic processes 
consistent with normal cell biology of the synthesis of proteins and GAGs 40,90. All of 
these features can be involved in pathology because growth factors can alter the 
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proteoglycan composition of the extracellular matrix by altering the relative 
expression of proteoglycan core proteins or independently by causing the elongation 
of the GAG chains, known as hyperelongation 14. Each of these processes regulating 
core proteins and GAG synthesis is activated by signaling pathways which are 
sometimes similar but can also be completely distinct 91. Considerable progress has 
been made in revealing the signaling pathways that control the synthesis and structure 
of proteoglycans in vascular smooth muscle from the hormone and growth factors 
39,92-94, metabolic factors 36 through to the involvement of transcription factors 95 that 
regulate the genes that control growth factor stimulated proteoglycan synthesis. 
Amongst these factors TGF-β is one of the most prominent activators of proteoglycan 
syntheses and it leads to increased binding to LDL. Given the established association 
between hyperglycemia and elevated TGF-β we have speculated that elevated TGF-β 
levels in diabetes play a pathogenic role in the development of accelerated 
atherosclerosis in diabetes. Blocking growth factor actions on proteoglycan synthesis 
with many known cardiovascular and diabetes drugs attenuates lipid binding and 
potential provides pleiotropic actions which assist in the prevention of atherosclerosis 
96,97. These signaling pathways have the potential to be therapeutic targets for vascular 
diseases such as atherosclerosis especially when targeted by highly specific agents 
34,35. Further studies will reveal the potential for these pathways to represent 
therapeutic targets that may be successfully exploited without interfering with the 
normal physiological functions of TGF-β. 
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Figures 
Figure 1. Atherosclerotic plaques show expression of TGF-β. Sections of abdominal 
aorta from a hypercholesterolemia non-human primate, Macaca nemestrina, and 
containing advanced fibrous plaques were immunostained with antibodies specific for 
control IgG (left panel) and with TGF-β1 (right panel). Positive staining for TGF-β1 
was seen in macrophages in the core of the lesion as well as macrophages scattered in 
the fibrous cap and near the luminal surface. Magnification, X60.  
Reprinted from Am J Pathol 1998, 152:533-546 with permission from the American 
Society for Investigative Pathology. 
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Figure 2. Schema showing our current knowledge of the signaling pathway through 
which Transforming  Growth Factor (TGF)-β stimulates changes in the synthesis and 
structure of proteoglycans secreted by vascular smooth muscle cells. These changes 
lead to increased in vitro binding of proteoglycan to LDL and given the established 
relationship between hyperglycemia and elevated TGF-β levels, these effects 
potentially underlie the increased atherosclerosis observed in people with diabetes. 
The pathway leading to the stimulation of biglycan synthesis involves the canonical as 
well as the MAP kinase linker region phosphorylation pathway (see text for details 
and references). Erk: Extracellular regulated kinase; p38: p38 Mitogen Activated 
Protein (MAP) kinases; TβRI and TβRII are the Type I and II TGF-β receptors, 
respectively. Smad is the Smad transcription factors as part of the TβRI signaling 
pathways. 
 
 
Page 18 of 24 
Acknowledgments 
This study was supported by National Health and Medical Research Council project 
grant (#472611) (PJL) and Fellowship (PJL) and a National Heart Foundation of 
Australia grant-in-aid (PJL).  
Page 19 of 24 
References 
 
1. A. Hozawa, A.R. Folsom, A.R. Sharrett, and L.E. Chambless, Absolute and 
attributable risks of cardiovascular disease incidence in relation to optimal and 
borderline risk factors: comparison of African American with white subjects--
Atherosclerosis Risk in Communities Study. Arch Intern Med 2007; 167: 573-
9. 
2. P.Z. Zimmet, D.J. McCarty, and M.P. de Courten, The global epidemiology of non-
insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes 
Complications 1997; 11: 60-8. 
3. K.J. Hunt, R.G. Resendez, K. Williams, S.M. Haffner, and M.P. Stern, National 
Cholesterol Education Program versus World Health Organization metabolic 
syndrome in relation to all-cause and cardiovascular mortality in the San 
Antonio Heart Study. Circulation 2004; 110: 1251-7. 
4. A. Pfeiffer, and H. Schatz, Diabetic microvascular complications and growth 
factors. Experimental and Clinical Endocrinology and Diabetes 1995; 103: 7-
14. 
5. A.I. Adler, I.M. Stratton, H.A. Neil, et al., Association of systolic blood pressure 
with macrovascular and microvascular complications of type 2 diabetes 
(UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9. 
6. S.S. Soedamah-Muthu, J.H. Fuller, H.E. Mulnier, et al., All-cause mortality rates in 
patients with type 1 diabetes mellitus compared with a non-diabetic population 
from the UK general practice research database, 1992-1999. Diabetologia 
2006: 1-7. 
7. J. Nigro, N. Osman, A.M. Dart, and P.J. Little, Insulin Resistance and 
Atherosclerosis. Endocr Rev 2006; 27: 242-259. 
8. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso, Mortality from 
coronary heart disease in subjects with type 2 diabetes and in nondiabetic 
subjects with and without prior myocardial infarction. N Engl J Med 1998; 
339: 229-34. 
9. G. Howard, D.H. O'Leary, D. Zaccaro, et al., Insulin sensitivity and atherosclerosis. 
The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. 
Circulation 1996; 93: 1809-17. 
10. R. Ross, The pathogenesis of atherosclerosis. N Engl J Med 1986; 314: 488-500. 
11. R. Ross, Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-
26. 
12. P. Libby, Vascular biology of atherosclerosis: overview and state of the art. Am J 
Cardiol 2003; 91: 3A-6A. 
13. K.J. Williams, and I. Tabas, The response-to-retention hypothesis of early 
atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-61. 
14. P.J. Little, N. Osman, and K.D. O'Brien, Hyperelongated biglycan: the 
surreptitious initiator of atherosclerosis. Current Opinion in Lipidology 2008; 
19: 448-454. 
15. M.J. Davies, Stability and instability: two faces of coronary atherosclerosis. The 
Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20. 
16. E. Falk, Morphologic features of unstable atherothrombotic plaques underlying 
acute coronary syndromes. Am J Cardiol 1989; 63: 114E-120E. 
Page 20 of 24 
17. R. Cooper, J. Cutler, P. Desvigne-Nickens, et al., Trends and disparities in 
coronary heart disease, stroke, and other cardiovascular diseases in the United 
States: findings of the national conference on cardiovascular disease 
prevention. Circulation 2000; 102: 3137-47. 
18. P. Gaede, P. Vedel, N. Larsen, et al., Multifactorial intervention and 
cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 
348: 383-93. 
19. A.V. Finn, M.C. Kramer, M. Vorpahl, F.D. Kolodgie, and R. Virmani, 
Pharmacotherapy of coronary atherosclerosis. Expert Opin Pharmacother 
2009; 10: 1587-603. 
20. J.A. Beckman, M.A. Creager, and P. Libby, Diabetes and atherosclerosis: 
epidemiology, pathophysiology, and management. Jama 2002; 287: 2570-81. 
21. C. Berry, S. Noble, J.C. Gregoire, et al., Glycaemic status influences the nature 
and severity of coronary artery disease. Diabetologia53: 652-8. 
22. S.E. Nissen, and K. Wolski, Effect of rosiglitazone on the risk of myocardial 
infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 
2457-71. 
23. G.A. Diamond, L. Bax, and S. Kaul, Uncertain Effects of Rosiglitazone on the 
Risk for Myocardial Infarction and Cardiovascular Death. Ann Intern Med 
2007. 
24. A. Chait, and K.E. Bornfeldt, Diabetes and atherosclerosis: is there a role for 
hyperglycemia? J Lipid Res 2009; 50 Suppl: S335-9. 
25. R. Ross, and J.A. Glomset, The pathogenesis of atherosclerosis (second of two 
parts). N Engl J Med 1976; 295: 420-5. 
26. I. Tabas, K.J. Williams, and J. Boren, Subendothelial lipoprotein retention as the 
initiating process in atherosclerosis: update and therapeutic implications. 
Circulation 2007; 116: 1832-44. 
27. J.A. Berliner, M. Navab, A.M. Fogelman, et al., Atherosclerosis: basic 
mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 
2488-96. 
28. M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. 
Nature 2001; 414: 813-20. 
29. M.E. Cooper, F. Bonnet, M. Oldfield, and K. Jandeleit-Dahm, Mechanisms of 
diabetic vasculopathy: an overview. Am J Hypertens 2001; 14: 475-86. 
30. Y. Nakashima, H. Fujii, S. Sumiyoshi, T.N. Wight, and K. Sueishi, Early human 
atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings 
followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007; 27: 
1159-65. 
31. Y. Nakashima, T.N. Wight, and K. Sueishi, Early atherosclerosis in humans: role 
of diffuse intimal thickening and extracellular matrix proteoglycans. 
Cardiovasc Res 2008; 79: 14-23. 
32. T.N. Wight, Proteoglycans in pathological conditions: atherosclerosis. Fed Proc 
1985; 44: 381-5. 
33. G. Camejo, E. Hurt-Camejo, U. Olsson, and G. Bondjers, Proteoglycans and 
lipoproteins in atherosclerosis. Curr Opin Lipidol 1993; 4: 385-391. 
34. P.J. Little, M.L. Ballinger, and N. Osman, Vascular wall proteoglycan synthesis 
and structure as a target for the prevention of atherosclerosis. Vascular Health 
Risk Management 2007; 3: 1-8. 
Page 21 of 24 
35. M.L. Ballinger, J. Nigro, K.V. Frontanilla, A.M. Dart, and P.J. Little, Regulation 
of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci 2004; 61: 
1296-306. 
36. L. Tannock, P.J. Little, T.N. Wight, and A. Chait, Arterial smooth muscle cell 
proteoglycans synthesized in the presence of glucosamine demonstrate 
reduced binding to LDL. J Lipid Res 2002; 43: 149-157. 
37. P. Wilson, K. Drennon, and L.R. Tannock, Regulation of vascular proteoglycan 
synthesis by metabolic factors associated with diabetes. J Investig Med 2007; 
55: 18-25. 
38. P.J. Little, K.D. Drennon, and L.R. Tannock, Glucosamine inhibits the synthesis 
of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by 
depletion of ATP. Arch Physiol Biochem 2008; 114: 120-6. 
39. P.J. Little, L. Tannock, K.L. Olin, A. Chait, and T.N. Wight, Proteoglycans 
synthesized by arterial smooth muscle cells in the presence of transforming 
growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb 
Vasc Biol 2002; 22: 55-60. 
40. J.E. Silbert, and G. Sugumaran, Biosynthesis of chondroitin/dermatan sulfate. 
IUBMB Life 2002; 54: 177-86. 
41. P. Arner, Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab 
Res Rev 2002; 18 Suppl 2: S5-9. 
42. U. Olsson, G. Bondjers, and G. Camejo, Fatty acids modulate the composition of 
extracellular matrix in cultured human arterial smooth muscle cells by altering 
the expression of genes for proteoglycan core proteins. Diabetes 1999; 48: 
616-22. 
43. K. Sharma, F.N. Ziyadeh, B. Alzahabi, et al., Increased renal production of 
transforming growth factor-beta1 in patients with type II diabetes. Diabetes 
1997; 46: 854-9. 
44. E. Schonherr, H.T. Jarvelainen, L.J. Sandell, and T.N. Wight, Effects of platelet-
derived growth factor and transforming growth factor-beta 1 on the synthesis 
of a large versican-like chondroitin sulfate proteoglycan by arterial smooth 
muscle cells. J Biol Chem 1991; 266: 17640-7. 
45. E. Schonherr, H.T. Jarvelainen, M.G. Kinsella, L.J. Sandell, and T.N. Wight, 
Platelet-derived growth factor and transforming growth factor-beta 1 
differentially affect the synthesis of biglycan and decorin by monkey arterial 
smooth muscle cells. Arterioscler Thromb 1993; 13: 1026-36. 
46. H. Dadlani, M.L. Ballinger, N. Osman, R. Getachew, and P.J. Little, Smad and 
p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular 
smooth muscle. J Biol Chem 2008; 283: 7844-52. 
47. M.L. Burch, S.N. Yang, M.L. Ballinger, et al., TGF-β stimulates biglycan 
synthesis via p38 and ERK phosphorylation of the linker region of Smad 2. 
Cell Mol Life Sci 2010 Accepted 12.02.2010. 
48. J. Massague, S.W. Blain, and R.S. Lo, TGFbeta signaling in growth control, 
cancer, and heritable disorders. Cell 2000; 103: 295-309. 
49. A. Agrotis, N. Kalinina, and A. Bobik, Transforming growth factor-beta, cell 
signaling and cardiovascular disorders. Curr Vasc Pharmacol 2005; 3: 55-61. 
50. R. Derynck, and Y.E. Zhang, Smad-dependent and Smad-independent pathways 
in TGF-beta family signalling. Nature 2003; 425: 577-84. 
51. L. Wu, and R. Derynck, Essential role of TGF-beta signaling in glucose-induced 
cell hypertrophy. Dev Cell 2009; 17: 35-48. 
Page 22 of 24 
52. A. Bobik, A. Agrotis, P. Kanellakis, et al., Distinct patterns of transforming 
growth factor-beta isoform and receptor expression in human atherosclerotic 
lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. 
Circulation 1999; 99: 2883-91. 
53. S.P. Evanko, E.W. Raines, R. Ross, L.I. Gold, and T.N. Wight, Proteoglycan 
distribution in lesions of atherosclerosis depends on lesion severity, structural 
characteristics, and the proximity of platelet-derived growth factor and 
transforming growth factor-beta. Am J Pathol 1998; 152: 533-46. 
54. J. Massague, TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-91. 
55. W.M. Grady, Transforming growth factor-beta, Smads, and cancer. Clin Cancer 
Res 2005; 11: 3151-4. 
56. Y. Taya, S. O'Kane, and M.W. Ferguson, Pathogenesis of cleft palate in TGF-
beta3 knockout mice. Development 1999; 126: 3869-79. 
57. J.J. Letterio, and A.B. Roberts, Transforming growth factor-beta1-deficient mice: 
identification of isoform-specific activities in vivo. J Leukoc Biol 1996; 59: 
769-74. 
58. D.G. Molin, M.C. DeRuiter, L.J. Wisse, et al., Altered apoptosis pattern during 
pharyngeal arch artery remodelling is associated with aortic arch 
malformations in Tgfbeta2 knock-out mice. Cardiovasc Res 2002; 56: 312-22. 
59. R. Derynck, J.A. Jarrett, E.Y. Chen, et al., Human transforming growth factor-beta 
complementary DNA sequence and expression in normal and transformed 
cells. Nature 1985; 316: 701-5. 
60. N. Khalil, TGF-beta: from latent to active. Microbes Infect 1999; 1: 1255-63. 
61. D.B. Rifkin, Latent transforming growth factor-beta (TGF-beta) binding proteins: 
orchestrators of TGF-beta availability. J Biol Chem 2005; 280: 7409-12. 
62. C.M. Dubois, M.H. Laprise, F. Blanchette, L.E. Gentry, and R. Leduc, Processing 
of transforming growth factor beta 1 precursor by human furin convertase. J 
Biol Chem 1995; 270: 10618-24. 
63. J.P. Annes, J.S. Munger, and D.B. Rifkin, Making sense of latent TGFbeta 
activation. J Cell Sci 2003; 116: 217-24. 
64. M.K. Lee, C. Pardoux, M.C. Hall, et al., TGF-beta activates Erk MAP kinase 
signalling through direct phosphorylation of ShcA. Embo J 2007; 26: 3957-67. 
65. J.J. Dore, Jr., M. Edens, N. Garamszegi, and E.B. Leof, Heteromeric and 
homomeric transforming growth factor-beta receptors show distinct signaling 
and endocytic responses in epithelial cells. J Biol Chem 1998; 273: 31770-7. 
66. S. Cheifetz, J.L. Andres, and J. Massague, The transforming growth factor-beta 
receptor type III is a membrane proteoglycan. Domain structure of the 
receptor. J Biol Chem 1988; 263: 16984-91. 
67. S. Munir, G. Xu, Y. Wu, et al., Nodal and ALK7 inhibit proliferation and induce 
apoptosis in human trophoblast cells. J Biol Chem 2004; 279: 31277-86. 
68. D. Javelaud, and A. Mauviel, Crosstalk mechanisms between the mitogen-
activated protein kinase pathways and Smad signaling downstream of TGF-
beta: implications for carcinogenesis. Oncogene 2005; 24: 5742-50. 
69. A. Moustakas, S. Souchelnytskyi, and C.H. Heldin, Smad regulation in TGF-beta 
signal transduction. J Cell Sci 2001; 114: 4359-69. 
70. J.W. Wu, M. Hu, J. Chai, et al., Crystal structure of a phosphorylated Smad2. 
Recognition of phosphoserine by the MH2 domain and insights on Smad 
function in TGF-beta signaling. Mol Cell 2001; 8: 1277-89. 
Page 23 of 24 
71. Y. Shi, A. Hata, R.S. Lo, J. Massague, and N.P. Pavletich, A structural basis for 
mutational inactivation of the tumour suppressor Smad4. Nature 1997; 388: 
87-93. 
72. F. Itoh, H. Asao, K. Sugamura, et al., Promoting bone morphogenetic protein 
signaling through negative regulation of inhibitory Smads. EMBO J 2001; 20: 
4132-42. 
73. M. Kretzschmar, J. Doody, I. Timokhina, and J. Massague, A mechanism of 
repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 1999; 
13: 804-16. 
74. P.D. Richardson, M.J. Davies, and G.V. Born, Influence of plaque configuration 
and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 
1989; 2: 941-4. 
75. G. Camejo, E. Hurt-Camejo, O. Wiklund, and G. Bondjers, Association of apo B 
lipoproteins with arterial proteoglycans: pathological significance and 
molecular basis. Atherosclerosis 1998; 139: 205-22. 
76. T.N. Wight, and M.J. Merrilees, Proteoglycans in atherosclerosis and restenosis: 
key roles for versican. Circ Res 2004; 94: 1158-67. 
77. Y. Yamaguchi, D.M. Mann, and E. Ruoslahti, Negative regulation of transforming 
growth factor-beta by the proteoglycan decorin. Nature 1990; 346: 281-4. 
78. M. Yanagishita, Function of proteoglycans in the extracellular matrix. Acta Pathol 
Jpn 1993; 43: 283-93. 
79. C.L. Lendon, M.J. Davies, G.V. Born, and P.D. Richardson, Atherosclerotic 
plaque caps are locally weakened when macrophages density is increased. 
Atherosclerosis 1991; 87: 87-90. 
80. M.J. Davies, P.D. Richardson, N. Woolf, D.R. Katz, and J. Mann, Risk of 
thrombosis in human atherosclerotic plaques: role of extracellular lipid, 
macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81. 
81. S.T. Nikkari, H.T. Jarvelainen, T.N. Wight, M. Ferguson, and A.W. Clowes, 
Smooth muscle cell expression of extracellular matrix genes after arterial 
injury. Am J Pathol 1994; 144: 1348-56. 
82. M.J. Davies, N. Woolf, and W.B. Robertson, Pathology of acute myocardial 
infarction with particular reference to occlusive coronary thrombi. Br Heart J 
1976; 38: 659-64. 
83. K.J. Williams, G.M. Fless, K.A. Petrie, et al., Mechanisms by which lipoprotein 
lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and 
nascent lipoproteins. Roles for low density lipoprotein receptors and heparan 
sulfate proteoglycans. J Biol Chem 1992; 267: 13284-92. 
84. P.J. Little, M.L. Ballinger, M.L. Burch, and N. Osman, Biosynthesis of natural 
and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into 
an elusive process. Open Biochem J 2008; 2: 135-42. 
85. J. Boren, K. Olin, I. Lee, et al., Identification of the principal proteoglycan-
binding site in LDL. A single-point mutation in apo-B100 severely affects 
proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 
1998; 101: 2658-64. 
86. C. Flood, M. Gustafsson, P.E. Richardson, et al., Identification of the 
proteoglycan binding site in apolipoprotein B48. J Biol Chem 2002; 277: 
32228-33. 
Page 24 of 24 
87. H.F. Hoff, and W.D. Wagner, Plasma low density lipoprotein accumulation in 
aortas of hypercholesterolemic swine correlates with modifications in aortic 
glycosaminoglycan composition. Atherosclerosis 1986; 61: 231-6. 
88. P. Libby, Inflammation in atherosclerosis. Nature 2002; 420: 868-74. 
89. K. Dahl-Jorgensen, J.R. Larsen, and K.F. Hanssen, Atherosclerosis in childhood 
and adolescent type 1 diabetes: early disease, early treatment? Diabetologia 
2005; 48: 1445-53. 
90. T.N. Wight, Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-20. 
91. L.E.M. Cardoso, P.J. Little, M.L. Ballinger, et al., Platelet-derived growth factor 
differentially regulates the expression and post-translational modification of 
versican by arterial smooth muscle cells through distinct protein kinase C and 
exracellular signal-regulated kinase pathways. J Biol Chem 2009; Epub 
30.12.2009. 
92. M.L. Ballinger, N. Osman, K. Hashimura, et al., Imatinib inhibits vascular smooth 
muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic 
lipid deposition in vivo. Journal of Cellular and Molecular Medicine 2009; (in 
press). 
93. M.E. Ivey, and P.J. Little, Thrombin regulates vascular smooth muscle cell 
proteoglycan synthesis via PAR-1 and multiple downstream signalling 
pathways. Thromb Res 2008. 
94. M.L. Ballinger, M.E. Ivey, N. Osman, W.G. Thomas, and P.J. Little, Endothelin-1 
activates ETA receptors on human vascular smooth muscle cells to yield 
proteoglycans with increased binding to LDL. Atherosclerosis 2009; 205: 451-
7. 
95. S.N. Yang, M.L. Burch, R. Getachew, et al., Growth factor-mediated hyper-
elongation of glycosaminoglycan chains on biglycan requires transcription and 
translation. Arch Physiol Biochem 2009; 115: 147-54. 
96. J. Nigro, R.J. Dilley, and P.J. Little, Differential effects of gemfibrozil on 
migration, proliferation and proteoglycan production in human vascular 
smooth muscle cells. Atherosclerosis 2002; 162: 119-29. 
97. S.T. de Dios, K.V. Frontanilla, J. Nigro, et al., Regulation of the atherogenic 
properties of vascular smooth muscle proteoglycans by oral anti-
hyperglycemic agents. J Diabetes Complications 2007; 21: 108-17. 
 
 
